Vnitr Lek 2026, 72(3):171-175 | DOI: 10.36290/vnl.2026.036

Hypolipidemic therapy in pregnancy

Pavla Jadrníčková1, 2, Jan Václavík1, 2, Filip Dubský1, 2
1 Interní a kardiovaskulární oddělení, Fakultní nemocnice Ostrava
2 Lékařská fakulta, Ostravská univerzita, Ostrava

Pregnancy is accompanied by significant metabolic adaptations, including a physiological increase in lipid levels, particularly low-density lipoprotein cholesterol (LDL-C), a causal risk factor for cardiovascular disease. Elevated LDL-C exposure during gestation, especially in women with familial hypercholesterolemia (FH), contributes to lifelong cardiovascular risk. Although atherosclerotic coronary artery disease is rare in women of reproductive age, pregnancy in the fourth and fifth decades of life is becoming increasingly common and is associated with a higher prevalence of acute myocardial infarction during pregnancy. This review summarizes current strategies for managing dyslipidemia during pregnancy. Non-pharmacological measures, such as appropriate nutrition (e.g., Mediterranean diet) and regular physical activity, form the cornerstone of management. Pharmacotherapy is limited: bile acid sequestrants and LDL apheresis are considered safe, while ezetimibe, PCSK9 inhibitors, bempedoic acid, and volanesorsen are contraindicated due to insufficient safety data, although recent evidence supports the continuation of statins in high-risk patients. In cases of markedly elevated Lp(a), regular LDL apheresis can substantially reduce atherogenic burden. Monitoring of lipid profiles and an individualized approach, ideally within a multidisciplinary team, are essential to minimize maternal and fetal risks. This review highlights the need for further research to optimize pharmacological treatment of dyslipidemia during pregnancy and to establish safe therapeutic strategies for women at high cardiovascular risk.

Keywords: apheresis, lipid-lowering agents, pregnancy, LDL-cholesterol.

Accepted: April 23, 2026; Published: May 18, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jadrníčková P, Václavík J, Dubský F. Hypolipidemic therapy in pregnancy. Vnitr Lek. 2026;72(3):171-175. doi: 10.36290/vnl.2026.036.
Download citation

References

  1. Mulder JWCM, Kusters DM, Roeters Van Lennep JE, Hutten BA. Lipid metabolism during pregnancy: consequences for mother and child. Curr Opin Lipidol. 2024;35(3):133-140. doi:10.1097/MOL.0000000000000927. Go to original source... Go to PubMed...
  2. Národní Registr Reprodukčního Zdraví. https://www.uzis.cz/index.php?pg=registry-sber-dat--narodni-zdravotni-registry--narodni-registr-reprodukcniho-zdravi
  3. Ascarelli M, Grider A, Hsu H. Acute myocardial infarction during pregnancy managed with immediate percutaneous transluminal coronary angioplasty. Obstet Gynecol. 1996;88(4):655-657. doi:10.1016/0029-7844(96)00288-8. Go to original source... Go to PubMed...
  4. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: A systematic review. J Clin Lipidol. 2016;10(5):1081-1090. doi:10.1016/j.jacl.2016. 07. 002. Go to original source...
  5. Cao L, Du Y, Zhang M, et al. High maternal blood lipid levels during early pregnancy are associated with increased risk of congenital heart disease in offspring. Acta Obstet Gynecol Scand. 2021;100(10):1806-1813. doi:10.1111/aogs.14225. Go to original source... Go to PubMed...
  6. Papazoglou AS, Moysidis DV, Panagopoulos P, et al. Maternal diabetes mellitus and its impact on the risk of delivering a child with congenital heart disease: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2022;35(25):7685-7694. doi:10.1080/14767058.2021.1960968. Go to original source... Go to PubMed...
  7. Ryan EA, Enns L. Role of Gestational Hormones in the Induction of Insulin Resistance*. J Clin Endocrinol Metab. 1988;67(2):341-347. doi:10.1210/jcem-67-2-341. Go to original source... Go to PubMed...
  8. Martin-Hidalgo A, Holm C, Belfrage P, Schotz MC, Herrera E. Lipoprotein lipase and hormone-sensitive lipase activity and mRNA in rat adipose tissue during pregnancy. Am J Physiol-Endocrinol Metab. 1994;266(6):E930-E935. doi:10.1152/ajpendo.1994.266. 6. E930. Go to original source...
  9. Wiznitzer A, Mayer A, Novack V, et al. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol. 2009;201(5):482.e1-482.e8. doi:10.1016/j.ajog.2009. 05. 032. Go to original source...
  10. Golwala S, Dolin CD, Nemiroff R, et al. Feasibility of Lipid Screening During First Trimester of Pregnancy to Identify Women at Risk of Severe Dyslipidemia. J Am Heart Assoc. 2023;12(10):e028626. doi:10.1161/JAHA.122.028626. Go to original source... Go to PubMed...
  11. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277-2291. doi:10.1093/eurheartj/ehad197. Go to original source... Go to PubMed...
  12. Healthy Pregnancy: What Foods to Eat When Pregnant. Last Updated 01 August 2021. https://www.eufic.org/en/healthy-living/article/healthy-pregnancy-what-foods-to-eat-when-pregnant (accessed on 19 July 2025).
  13. Davenport MH, Kathol AJ, Mottola MF, et al. Prenatal exercise is not associated with fetal mortality: a systematic review and meta-analysis. Br J Sports Med. 2019;53(2):108-115. doi:10.1136/bjsports-2018-099773. Go to original source...
  14. De Backer J, Haugaa KH, Hasselberg NE, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193. Go to original source... Go to PubMed...
  15. Jadrnickova P, Vaclavik J, Jarkovsky J, Zouharova A. Maternal and fetal outcomes of various lipid-lowering treatment regimens during pregnancy: insights from the czech national registry 2012-2023. Eur Heart J. 2025;46(Supplement_1):ehaf784.3444. doi:10.1093/eurheartj/ehaf784.3444. Go to original source...
  16. FDA. Cholestyramine powder for suspension. https://fda.report/DailyMed/ac385fd9-fb8c-461f-959c-322c38f4515e.
  17. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and Safety of Ursodeoxycholic Acid Versus Cholestyramine in Intrahepatic Cholestasis of Pregnancy. Gastroenterology. 2005;129(3):894-901. doi:10.1053/j.gastro.2005. 06. 019. Go to original source...
  18. Sadler LC, Lane M, North R. Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. BJOG Int J Obstet Gynaecol. 1995;102(2):169-170. doi:10.1111/j.1471-0528.1995.tb09077.x. Go to original source... Go to PubMed...
  19. Gordon BR, Stein E, Jones P, Illingworth DR. Indications for low-density lipoprotein apheresis. Am J Cardiol. 1994;74(11):1109-1112. doi:10.1016/0002-9149(94)90461-8. Go to original source... Go to PubMed...
  20. Bláha V, Zadák Z, Bláha M, et al. (Selection criteria for treatment of severe hyperlipoproteinemias with LDL apheresis). Cas Lek Cesk. 1998;137(14):424-429.
  21. Makino H, Koezuka R, Tamanaha T, et al. Familial Hypercholesterolemia and Lipoprotein Apheresis. J Atheroscler Thromb. 2019;26(8):679-687. doi:10.5551/jat.RV17033. Go to original source... Go to PubMed...
  22. Bláha M, Veletová K, Blaha V, Lánská M, Žák P. Pregnancy in homozygous familial hypercholesterolemia-A case series. Ther Apher Dial. 2022;26(S1):89-96. doi:10.1111/1744-9987.13841. Go to original source...
  23. Ogura M, Makino H, Kamiya C, et al. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. Atherosclerosis. 2016;254:179-183. doi:10.1016/j.atherosclerosis.2016. 10. 018. Go to original source...
  24. Marlęga-Linert J, Wartecka-Zielińska K, Wydra D, Fijałkowski M, Gruchała M, Mickiewicz A. Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia. Front Med. 2023;10:1190446. doi:10.3389/fmed.2023.1190446. Go to original source... Go to PubMed...
  25. FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins During Pregnancy. Published online August 14, 2024. https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requests-removalstrongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy.
  26. Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG Int J Obstet Gynaecol. 2013;120(4):463-471. doi:10.1111/1471-0528.12066. Go to original source... Go to PubMed...
  27. McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss. Pharmacoepidemiol Drug Saf. 2017;26(7):843-852. doi:10.1002/pds.4176. Go to original source... Go to PubMed...
  28. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350(mar17 10):h1035-h1035. doi:10.1136/bmj.h1035. Go to original source... Go to PubMed...
  29. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251-261. doi:10.1016/j.atherosclerosis.2012. 02. 016. Go to original source...
  30. Wild R, Feingold KR. Effect of Pregnancy on Lipid Metabolism and Lipoprotein Levels. (Updated 2023 Mar 3). In: Feingold KR, Adler RA, Ahmed SF, et al., editors. Endotext (Internet). https://www.ncbi.nlm.nih.gov/books/NBK498654/.
  31. Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047-5057. doi:10.1093/eurheartj/ehac615. Go to original source... Go to PubMed...
  32. Ardissino M, Slob EAW, Reddy RK, et al. Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations. Eur J Prev Cardiol. 2024;31(8):955-965. doi:10.1093/eurjpc/zwad402. Go to original source... Go to PubMed...
  33. Noseda R, Bedussi F, Panchaud A, Ceschi A. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®. Clin Pharmacol Ther. 2024;116(2):346-350. doi:10.1002/cpt.3269. Go to original source... Go to PubMed...
  34. Laffin LJ, Nicholls SJ, Scott RS, et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. N Engl J Med. 2025;393(21):2119-2130. doi:10.1056/NEJMoa2511778. Go to original source... Go to PubMed...
  35. Middleton P, Gomersall JC, Gould JF, et al. Omega-3 fatty acid addition during pregnancy. Cochrane Pregnancy and Childbirth Group, ed. Cochrane Database Syst Rev. 2018;2018(11). doi:10.1002/14651858.CD003402.pub3. Go to original source... Go to PubMed...
  36. Agarwala A, Dixon DL, Gianos E, et al. Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e664-e684. doi:10.1016/j.jacl.2024. 05. 005. Go to original source...
  37. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205(1):1-8. doi:10.1016/j.atherosclerosis.2009. 03. 008. Go to original source...
  38. Grady J, Clifford C, Treadwell MC, Parikh ND, Satishchandran A. Use of fenofibrate for intrahepatic cholestasis of pregnancy. J Hepatol. 2023;79(2):e84-e86. doi:10.1016/j.jhep.2023. 04. 014. Go to original source...
  39. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11). doi:10.1161/CIR.0000000000000678. Go to original source...
  40. Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Heart Group, ed. Cochrane Database Syst Rev. 2016;2017(3). doi:10.1002/14651858.CD009753.pub2. Go to original source... Go to PubMed...
  41. Wanninayake S, Ochoa-Ferraro A, Patel K, Ramachandran R, Wierzbicki AS, Dawson C. Two successful pregnancies in patients taking Volanesorsen for familial chylomicronemia syndrome. JIMD Rep. 2024;65(4):249-254. doi:10.1002/jmd2.12435. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.